Thyrocare has come out with its maiden results on 11/6/2016 . The company has also declared final dividend of 25% thus making the total dividend payout as 100% (Rs. 10/-). The results are ok but not phenomenal. Along with Dr. Lal Path Labs Thyrocare Technologies Ltd. is the only listed company in organized diagnostics space.
Though full details are yet not available, the company seems to be cruising well. It has posted a decent 31% top line growth and PBT growth of 21%. Thus profits seem to growing but albeit at a little slower pace than the revenues. The PAT was grown by 17.7% on account of increased taxation. The company is cash rich and has incurred zero financial charges. Thyrocare has pioneered a unique model of single computerized Lab & collection of samples at door step.
Thyrocare Results all figures in Rs. Million
| Q4 fy2016 | Annual fye 2016 | Annual fye 2015 |
Total Income | 651 | 2410 | 1829 |
PBT | 218 | 818 | 678 |
PAT | 139 | 518 | 440 |
Equity | 537 | 537 | 505 |
EPS | 2.71 | 10.06 | 9.14 |
Thyrocare vs Dr.Lal PathLabs (all figures in Rs. Million)
| Thyrocare ( fye 2016) | Dr. Lal Path Labs (fye 2016) |
Total Income | 2410 | 7858 |
PBT | 818 | 1918 |
PAT | 518 | 1258 |
Equity | 537 | 827 |
EPS | 10.06 | 15.31 |
Dividend | 100% | 24.2% |
Market Price (10/6/16) | 604 | 988 |
PE ratio | 60 | 64.5 |
Net Profit Margin | 21.5 | 16 |